Elranatamab in relapsed/refractory multiple myeloma patients on hemodialysis: A real-world case series
Hikmettullah Batgi, Fatoş Dilan Köseoğlu, Denis Çetin, Semih Başcı, Sinem Namdaroğlu, Nur Akad Soyer · 2026
Read Elranatamab in relapsed/refractory multiple myeloma patients on hemodialysis: A real-world case series by Hikmettullah Batgi, Fatoş Dilan Köseoğlu, Denis Çetin, Semih Başcı, Sinem Namdaroğlu, Nur Akad Soyer (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13625312.txt.
Description
Hikmettullah Batgi and colleagues share real-world results for a modern myeloma drug in patients whose kidneys had failed. Four people on hemodialysis, aged sixty-one to eighty, received elranatamab, an antibody that links immune cells to a marker on myeloma cells. Each had already failed a median of six earlier treatment lines, including the three main drug classes, and dialysis patients are usually shut out of the trials that approve such drugs.
Every patient responded, two completely, and all four stayed on treatment at the report's cutoff. One had a mild, self-settling fever reaction, and one survived severe pneumonia in intensive care, then resumed the drug and kept the complete response. The small series hints the therapy can work even when kidneys cannot clear drugs normally.
Catalog record
| CREATOR | Hikmettullah Batgi, Fatoş Dilan Köseoğlu, Denis Çetin, Semih Başcı, Sinem Namdaroğlu, Nur Akad Soyer |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 18 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |